Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Frontiers in Genetics|April 3, 2023
Severe nephrotic syndrome and early end-stage diabetic kidney disease in <i>ABCC8</i>-MODY12: A case reportSophie H Schmidt, Ursula Barnas, Christof Aigner, et al.
European Journal of Pharmacology|January 22, 2017
Emodin, a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodentsSameer Abu Eid, Michael Adams, Thomas Scherer, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Evidence that the multiflorine-derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α<sub>2</sub> -adrenoceptors in miceZsuzsanna Lehner, Karin Stadlbauer, Barbara Brunmair, et al.
Frontiers in Endocrinology|September 14, 2018
Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in MiceSameer Abu Eid, Martina T Hackl, Mairam Kaplanian, et al.
NMR in Biomedicine|December 15, 2024
Deuterium Metabolic Imaging Enables the Tracing of Substrate Fluxes Through the Tricarboxylic Acid Cycle in the LiverViktoria Ehret, Sabine C Dürr, Usevalad Ustsinau, et al.
Inorganic Chemistry|July 1, 2011
Reductive approach to mixed valency (n = 1-) in the pyrazine ligand-bridged [(acac)2Ru(μ-L(2-))Ru(acac)2](n) (L(2-) = 2,5-pyrazine-dicarboxylate) through experiment and theoryAmit Das, Thomas Scherer, Somnath Maji, et al.
Endocrinology|July 9, 2013
Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male miceJose M Garcia, Thomas Scherer, Ji-an Chen, et al.
Metabolism: Clinical and Experimental|December 26, 2021
Deciphering metformin action in obese mice: A critical re-evaluation of established protocolsMairam Kaplanian, Cecile Philippe, Sameer Abu Eid, et al.
Cancers|November 26, 2022
Is Regular Radiographic Upper Urinary Tract Imaging for Surveillance of Non-Muscle Invasive Bladder Cancer Justified?Uwe Bieri, Benedikt Kranzbühler, Burkhardt Seifert, et al.
Molecular Genetics and Metabolism Reports|May 20, 2024
Poor adherence during adolescence is a risk factor for becoming lost-to-follow-up in patients with phenylketonuriaMarianna Beghini, Maximilian Pichler, Fiona Carolina Tinnefeld, et al.
Pageof 10